Ondrej Kalous

List of Publications by Year
in descending order

15	1,860	687363 13	1125743 13
papers	citations	h-index	g-index

15	15	15	3544
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research, 2009, 11, R77.	5.0	1,131
2	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research, 2014, 20, 3507-3520.	7.0	100
3	A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Molecular Cancer Therapeutics, 2007, 6, 886-897.	4.1	90
4	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics, 2018, 17, 897-907.	4.1	77
5	Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. Molecular Cancer Therapeutics, 2012, 11, 1978-1987.	4.1	68
6	Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Molecular Cancer Therapeutics, 2013, 12, 509-519.	4.1	66
7	Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex. Clinical Cancer Research, 2007, 13, 3079-3086.	7.0	58
8	Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity. Clinical Cancer Research, 2008, 14, 533-540.	7.0	53
9	DIMSCAN: A Microcomputer Fluorescence-Based Cytotoxicity Assay for Preclinical Testing of Combination Chemotherapy. , 2005, 110, 139-154.		46
10	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment, 2015, 149, 669-680.	2.5	46
11	Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 3094-3109.	4.1	43
12	Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma. Clinical Cancer Research, 2011, 17, 7093-7104.	7.0	34
13	Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. Genes Chromosomes and Cancer, 2017, 56, 589-597.	2.8	27
14	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Research and Treatment, 2013, 141, 397-408.	2.5	21
15	557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer. European Journal of Cancer, Supplement, 2008, 6, 175-176.	2.2	0